COPD is characterized by increased detection of Haemophilus influenzae, Streptococcus pneumoniae and a deficiency of Bacillus species

Respirology

Volumn 21, Issue 4, 2016, Pages 697-704

  Simpson, Jodie L ^a   Baines, Katherine J ^a   Horvat, Jay C ^a   Essilfie, Ama Tawiah ^a   Brown, Alexandra C ^a   Tooze, Melinda ^a   McDonald, Vanessa M ^a,b   Gibson, Peter G ^a,b   Hansbro, Philip M ^a  

^a HUNTER MEDICAL RESEARCH INSTITUTE   (Australia)

^b JOHN HUNTER HOSPITAL   (Australia)

Author keywords

bacteria; chronic obstructive pulmonary disease; inflammation; pathogen

Indexed keywords

INTERLEUKIN 1BETA; LEUKOCYTE ELASTASE;

ADULT; ARTICLE; BACILLUS; BACTERIAL LOAD; BACTERIUM CULTURE; BACTERIUM DETECTION; CELL COUNT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; EMPHYSEMA; FEMALE; HAEMOPHILUS INFLUENZAE; HUMAN; INFLAMMATION; LUNG DIFFUSION CAPACITY; LUNG INSUFFICIENCY; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; PATHOGENESIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SMOKING; SPUTUM ANALYSIS; SPUTUM LEVEL; ST. GEORGE RESPIRATORY QUESTIONNAIRE; STREPTOCOCCUS PNEUMONIAE; SUPERNATANT; AGED; CASE CONTROL STUDY; CHEMISTRY; CYTOLOGY; ISOLATION AND PURIFICATION; LEUKOCYTE COUNT; MICROBIOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; QUESTIONNAIRE; SPUTUM; YOUNG ADULT;

ADULT; AGED; BACILLUS; BACTERIAL LOAD; CASE-CONTROL STUDIES; FEMALE; HAEMOPHILUS INFLUENZAE; HUMANS; INTERLEUKIN-1BETA; LEUKOCYTE COUNT; LEUKOCYTE ELASTASE; MALE; MIDDLE AGED; NEUTROPHILS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPUTUM; STREPTOCOCCUS PNEUMONIAE; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 84955296344     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12734     Document Type: Article

References (34)

1. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370: 741-750.
2. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS,. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. Am. J. Respir. Crit. Care Med. 2001; 163: 1256-1276.
3. Agusti A, Barnes PJ,. What the journal would like to publish on chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2010; 182: 1-2.
4. Haq K, McElhaney JE,. Ageing and respiratory infections: the airway of ageing. Immunol. Lett. 2014; 162: 323-328.
5. Simpson JL, McDonald VM, Baines KJ, Oreo KM, Wang F, Hansbro PM, Gibson PG,. Influence of age, past smoking, and disease severity on TLR2, neutrophilic inflammation, and MMP-9 levels in COPD. Mediators Inflamm. 2013; 2013: 462934.
6. Wilkinson TMA, Patel IS, Wilks M, Donaldson GC, Wedzicha JA,. Airway bacterial load and FEV1 decline in patient with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2003; 167: 1090-1095.
7. Sethi I, Evans N, Grant RNB, Murphy TF,. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N. Engl. J. Med. 2002; 347: 465-471.
8. Birrell BA, Patel HJ, McCluskie K, Wong S, Leonard T, Yacoub MH, Belvisi MG,. PPAR-gamma agonists as therapy for diseases involving airway neutrophilia. Eur. Resp. J. 2004; 24: 18-23.
9. Garcha DS, Thurston SJ, Patel AR, Mackay AJ, Goldring JJ, Donaldson GC, McHugh TD, Wedzicha JA,. Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax 2012; 67: 1075-1080.
10. Monso E, Ruiz J, Rosell A, Manterola J, Fiz J, Morera J, Ausina V,. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am. J. Respir. Crit. Care Med. 1995; 152: 1316-1320.
11. McDonald VM, Simpson JL, Higgins I, Gibson PG,. Multidimensional assessment of older people with asthma & COPD: clinical management and health status. Age. Ageing 2011; 40: 42-49.
12. Erb-Downward JR, Thompson DL, Han MK, Freeman CM, McCloskey L, Schmidt LA, Young VB, Toews GB, Curtis JL, Sundaram B, et al. Analysis of the lung microbiome in the 'healthy' smoker and in COPD. PLoS ONE 2011; 6: e16384.
13. Gibson PG, Wlodarczyk JW, Hensley MJ, Gleeson M, Henry RL, Cripps AR, Clancy RL,. Epidemiological association of airway inflammation with asthma symptoms and airway hyperresponsiveness in childhood. Am. J. Resp. Crit. Care. Med. 1998; 158: 36-41.
14. Essilfie A, Simpson J, Horvat J, Preston J, Dunkley M, Foster P, Gibson P, Hansbro P,. Haemophilus influenzae infection drives IL-17-mediated neutrophilic allergic airways disease. PLoS Pathog. 2011; 7: e1002244.
15. Essilfie AT, Simpson JL, Dunkley ML, Morgan LC, Oliver BG, Gibson PG, Foster PS, Hansbro PM,. Combined Haemophilus influenzae respiratory infection and allergic airways disease drives chronic infection and features of neutrophilic asthma. Thorax 2012; 67: 588-599.
16. Preston JA, Beagley KW, Gibson PG, Hansbro PM,. Genetic background affects susceptibility in nonfatal pneumococcal bronchopneumonia. Eur. Respir. J. 2004; 23: 224-231. doi: 10.1183/09031936.03.00081403.
17. Essilfie A-T, Horvat JC, Kim RY, Mayall JR, Pinkerton JW, Beckett EL, Starkey MR, Simpson JL, Foster PS, Gibson PG, et al. Macrolide therapy suppresses key features of experimental steroid-sensitive and steroid-insensitive asthma. Thorax 2015; 70: 458-467.
18. Preston JA, Thorburn AN, Starkey MR, Beckett EL, Horvat JC, Wade MA, O'Sullivan BJ, Thomas R, Beagley KW, Gibson PG, et al. Streptococcus pneumoniae infection suppresses allergic airways disease by inducing regulatory T-cells. Eur. Respir. J. 2011; 37: 53-64.
19. Marin A, Garcia-Aymerich J, Sauleda J, Belda J, Millares L, Garcia-Nunez M, Serra I, Benet M, Agusti A, Anto JM, et al. Effect of bronchial colonisation on airway and systemic inflammation in stable COPD. COPD 2012; 9: 121-130.
20. Desai H, Eschberger K, Wrona C, Grove L, Agrawal A, Grant B, Yin J, Parameswaran GI, Murphy T, Sethi S,. Bacterial colonization increases daily symptoms in patients with chronic obstructive pulmonary disease. Ann. Am. Thorac. Soc. 2014; 11: 303-309.
21. Simpson JL, Powell H, Baines KJ, Milne D, Coxson HO, Hansbro PM, Gibson PG,. The effect of azithromycin in adults with stable neutrophilic COPD: a double blind randomised, placebo controlled trial. PLoS ONE 2014; 9: e105609.
22. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JA Jr, Criner GJ, Curtis JL, Dransfield MT, Han MK, Lazarus SC, et al. Azithromycin for prevention of exacerbations of COPD. N. Engl. J. Med. 2011; 365: 689-698.
23. Curran T, Coyle PV, McManus TE, Kidney J, Coulter WA,. Evaluation of real-time PCR for the detection and quantification of bacteria in chronic obstructive pulmonary disease. FEMS Immunol. Med. Microbiol. 2007; 50: 112-118.
24. Barker BL, Haldar K, Patel H, Pavord ID, Barer MR, Brightling CE, Bafadhel M,. Association between pathogens detected using quantitative polymerase chain reaction with airway inflammation in COPD at stable state and exacerbations. Chest 2015; 147: 46-55.
25. Marin A, Monso E, Garcia-Nunez M, Sauleda J, Noguera A, Pons J, Agusti A, Morera J,. Variability and effects of bronchial colonisation in patients with moderate COPD. Eur. Respir. J. 2010; 35: 295-302.
26. Bafadhel M, Haldar K, Barker B, Patel H, Mistry V, Barer MR, Pavord ID, Brightling CE,. Airway bacteria measured by quantitative polymerase chain reaction and culture in patients with stable COPD: relationship with neutrophilic airway inflammation, exacerbation frequency, and lung function. Int. J. Chron. Obstruct. Pulmon. Dis. 2015; 10: 1075-1083.
27. Banerjee D, Khair OA, Honeybourne D,. Impact of sputum bacteria on airway inflammation and health status in clinical stable COPD. Eur. Resp. J. 2004; 23: 685-691.
28. Beckett EL, Stevens RL, Jarnicki AG, Kim RY, Hanish I, Hansbro NG, Deane A, Keely S, Horvat JC, Yang M, et al. A new short-term mouse model of chronic obstructive pulmonary disease identifies a role for mast cell tryptase in pathogenesis. J. Allergy Clin. Immunol. 2013; 131: 752-762.
29. Tay HL, Kaiko GE, Plank M, Li J, Maltby S, Essilfie AT, Jarnicki A, Yang M, Mattes J, Hansbro PM, et al. Antagonism of miR-328 increases the antimicrobial function of macrophages and neutrophils and rapid clearance of non-typeable Haemophilus influenzae (NTHi) from infected lung. PLoS Pathog. 2015; 11: e1004549.
30. Starkey MR, Jarnicki AG, Essilfie AT, Gellatly SL, Kim RY, Brown AC, Foster PS, Horvat JC, Hansbro PM,. Murine models of infectious exacerbations of airway inflammation. Curr. Opin. Pharmacol. 2013; 13: 337-344.
31. Fricker M, Deane A, Hansbro PM,. Animal models of chronic obstructive pulmonary disease. Expert. Opin. Drug Discov. 2014; 9: 629-645.
32. Chen-Yu Hsu A, Starkey MR, Hanish I, Parsons K, Haw TJ, Howland LJ, Barr I, Mahony JB, Foster PS, Knight DA, et al. Targeting PI3K-p110alpha suppresses influenza virus infection in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2015; 191: 1012-1023.
33. Pragman AA, Kim HB, Reilly CS, Wendt C, Isaacson RE,. The lung microbiome in moderate and severe chronic obstructive pulmonary disease. PLoS ONE 2012; 7: e47305.
34. Huang YJ, Sethi S, Murphy T, Nariya S, Boushey HA, Lynch SV,. Airway microbiome dynamics in exacerbations of chronic obstructive pulmonary disease. J. Clin. Microbiol. 2014; 52: 2813-2823.